Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.


Delayed Data
As of Nov 27
 -0.0294 / -2.97%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

GTx, Inc. operates as a biopharmaceutical company. It engages in the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for prostate and breast cancer, cancer supportive care, including prevention and treatment of cancer-related muscle wasting or cachexia, and other serious medical conditions. The company also develops selective androgen receptor modulators, a new class of drugs with the potential to prevent and treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia, as well as the potential to be used as a hormonal therapy for the treatment of metastatic breast cancer. Its SARM product candidate, enobosarm (GTx-024), has to date been evaluated in fourteen completed or ongoing clinical trials enrolling approximately 1,320 subjects, including in three Phase 2 and two Phase 3 clinical trials. GTx was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN.

Contact Information

GTx, Inc.
175 Toyota Plaza
Memphis Tennessee 38103
P:(901) 523-9700
Investor Relations:
(901) 271-8622



Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Marc Steven HanoverPresident, Chief Executive Officer & Director
Jason T. ShackelfordCFO, CAO, Accounting Director & Controller
Mary Ann JohnstonVP-Medical Affairs & Clinical Operations
Diane C. YoungChief Medical Officer & Vice President
Henry Patton DoggrellSecretary, Chief Legal Officer & Vice President